Dow Down1.40% Nasdaq Down1.59%




News & Info


Analyst Coverage

  • Analyst Opinion
  • Analyst Estimates


  • Major Holders
  • Insider Transactions
  • Insider Roster


  • Income Statement
  • Balance Sheet
  • Cash Flow


-Other OTC
65.75 0.00(0.00%) Sep 23
ProfileGet Profile for:
CSL Ltd.
45 Poplar Road
Parkville, VIC 3052
Australia - Map
Phone: 61 3 9389 1911
Fax: 61 3 9389 1434

Index Membership:N/A
Full Time Employees:12,196

Business Summary 

CSL Limited is engaged in the research, development, manufacture, marketing, and distribution of biopharmaceutical and allied products in Australia, the United States, Switzerland, Germany, and internationally. The company operates through CSL Behring, bioCSL, and CSL Intellectual Property segments. The CSL Behring segment manufactures, markets, and develops plasma products and recombinants that are used to treat coagulation disorders, including hemophilia and von Willebrand disease, primary immune deficiencies, hereditary angioedema and inherited respiratory disease, and neurological disorders, cardiac surgery, organ transplantation, and burn treatment, as well as to prevent hemolytic diseases in the newborn. The bioCSL segment manufactures and distributes non-plasma biotherapeutic products, including vaccines to protect against viral and bacterial diseases; pharmaceuticals to treat a range of human medical conditions; diagnostic products to determine compatibility of donor-recipient blood in transfusion settings; and antivenoms to treat victims of venomous snake and spider bites. The CSL Intellectual Property segment is engaged in the commercialization of intellectual property. In addition, the company markets various vaccines and antivenoms, as well as a range of pharmaceutical products supplied by other manufacturers. CSL Limited was founded in 1916 and is headquartered in Parkville, Australia.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on CSL Ltd.

Key Executives 
Mr. Paul R. Perreault BA Psychology, 57
Chief Exec. Officer, Managing Director, Exec. Director and Member of Innovation & Devel. Committee
Mr. Gordon Naylor Mba, Beng (Hons), Dipcompsc, 51
Chief Financial Officer
Dr. Andrew Cuthbertson BMedSci, MBBS, Ph.D., 59
Chief Scientific officer and Director of R&D
Mr. Gregory Boss J.D., BS(Hon), 53
Exec. VP of Legal, Group Gen. Counsel, Exec. VP of CSL Behring and Gen. Counsel of CSL Behring
Ms. Mary Sontrop B.Appsc, MBA, 57
Exec. VP of Manufacturing Operations & Planning
Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.